The Promising Shadow of Nanohybrid Liposomal Cerasomes towards the Treatment of Diabetes Mellitus

Abstract

Nanocarriers are used globally in diverse fields to encapsulate drug toovercome various problems associated with different drug delivery systems such asstability, solubility, improvement in functional activities, homogeneity, and protection from physical and chemical hazard destructions. In the field of biomedicine, this approachis considered to be of particular importance as it can easily overcome the issues related to biocompatibility, bioavailability, toxicity profile, and therapeutic side effects. Lipid-based delivery systems have evolved as a newer approach in drug delivery. Advancement, development, and design modification of the lipid-based drug delivery systems have given rise to hybrid structures containing both inorganic and organic parts called cerasomes. Cerasomes are a modified form of liposomes that can overcome the limitations related to lipid nanoparticles. However, these cerasomes are also effective in treating diabetes mellitus, which is a metabolic disorder that has affecteda vast population worldwide for the last few decades. The development of cerasomes for the treatment of diabetes has provided a new window for researchers to overcome the different problems connected to the current therapies. This article provides a thorough assessment of the hybrid liposomal cerasomes literature and how it can be effectively employed in the treatment of diabetes.